Introduction
Cyano-cob(III)alamin, also designated vitamin B12, is an essential, water soluble, and non-toxic vitamin even at high doses. Vitamin B12 is involved in the methionine synthesis and the tricarboxylic acid cycle. B12 comprises an octahedral Co III complex with a tetradentate corrin ring, an a-nucleotide loop and a CN À ligand in the b-axial position. The cyanide ligand can be exchanged for other monodentate functions (Fig. 1) . 1 Intracellular reduction of the Co III center subsequently forms square pyramidal cob(II)alamin and square planar cob(I)alamin, respectively. 2, 3 Enzymatic alkylation of cob(I)alamin in the cytosol and mitochondria leads to the formation of two B12-coenzymes with methyl and adenosyl as b-ligands. 4,5 B12 is protected from degradation inside living systems through its binding to the proteins haptocorrin (HC, present in saliva/ gastric fluids), intrinsic factor (IF, secreted by parietal cells), and transcobalamin (TC, plasma protein). 6, 7 Binding of B12 to TC is required for facilitating the uptake of the B12-TC complex via the TC-receptor or CD320 (across most membranes) and megalin (reabsorbed from the urine in kidney cells). 7 The B12 specificity follows the order: IF 4 TC c HC. [8] [9] [10] [11] Numerous functional groups on the corrin side chains, b-ligand, and a-nucleotide loop ( Fig. 1 ) are available to coordinate or conjugate drugs and analytical modalities. 12 The b-axial ligand is a preferred derivatization site owing to its ease-of-release in cellular environment and its little involvement in interaction with proteins. Nitrogen mustard chlorambucil, 13 colchicine, 14 cisplatin, 15 and insulinomimetic vanadate (V V ) compound 16 are drugs which have been bound to B12 at this site. In addition, fluorophores 17 and radionuclides 18, 19 have also been attached to B12 at this position. The ribosehydroxyl group is another convenient derivatization site as it is not involved in protein interaction. 20 Fluorophores, 21, 22 cytotoxic drugs, 23 insulin, 24 and appetite suppressing peptide hPYY 25 have been coupled to B12 via this position. Derivatization of B12, however, is not limited to the b-and ribose-positions. Radioactive 111 In-DTPA and 99m Tc-DTPA were coupled to B12 via the b-side chain. 26, 27 The { 99m Tc(CO) 3 } moiety was coupled to B12 via ligands coupled to the b-and d-side chains 28 and biotin via either the b-, c-, d-, or e-side chains. 12 Increasing structural knowledge of B12 and of its transport proteins is the base for fine-tuning the structures of biologically active B 12 derivatives and mimetics. Several B 12 antagonists were reported, including B12-[c-lactam], 29 and B12 with de novo peptide backbones. 30, 31 In addition, tissue distribution was interfered by modifying the B12 structure at a critical site (b-side chain) for protein interaction. 32 Research programs have been dedicated to explore the correlation of B12 requirements and DNA synthesis. This, however, is not the only advantage of using B12 as a carrier for anti-cancer drugs. Its water solubility allows convenient administration of the attached insoluble drugs. 15 B12 protects protein-peptide drugs 24, 25, 33 from hydrolysis in the acidic condition of the gastrointestinal track. 34 Though the utilization of B12 as drug carrier appeared to be restrained by its cellular loading capacity, 35 a recent study showed that tissue accumulation of B12 increased significantly (up to 350%) upon overdosing of the vitamin. 36 In this paper, B12 was applied as a drug carrier for cisplatin and as a carrier of the {fac-Re(CO) 3 } + moiety, which is a model moiety for Tc and Re radiopharmaceuticals. Cisplatin was chosen as it is the most often used platinum based drug in the clinic, its mode of action is binding to DNA in the nucleus, which triggers apoptosis and cell death. Cisplatin is taken up by the cells via passive diffusion or via active transport through the copper transporters (CTR1 and CTR2) and the organic cation transporters (OCTs) and possible also other pathways. 37 Once in the cell cisplatin undergoes aquation, chloride exchanged by water, forming positive ions which are more reactive towards the main biological target, DNA. 38 We determined the cytosolic and nucleic uptake of cisplatin, Pt NMR spectrum at À2354 ppm is in the same range as previously reported B12 derivatives containing {Co}-CN{-{Pt} bonds. 15, 40 Fig. 3 ), which further confirmed the presence of the rhenium complex.
Affinity of B12 derivatives towards transport proteins
Affinity to transport proteins of B12 derivatives was measured by Differential Scanning Fluorometry (DSF), where a fluorescent dye interacts with the hydrophobic sites of unfolded proteins and the melting temperature (T m ) of proteins can be inferred from the recorded fluorescence intensity. 41, 42 Following ligand binding, the protein stability is enhanced and the ligand-bound proteins unfold at higher temperature with respect to the free proteins. B12 derivatives which bind to B12 transport proteins would produce comparable DT m values to those of B12 while DT m values would be much lower if these derivatives do not bind to B12 transport proteins. In Fig. 4 , B12 was used as a positive control for the three transport proteins and cobinamide (Cbi) was used as a negative control. 42 Despite the chemical modification of the B12 structure, compound 2 retained good affinity to all B12 transport proteins as it has comparable DT m values to those of B12. Re reveal the intracellular distribution of these compounds. Fig. 5A shows the cellular cisplatin uptake in K562 cells, determined as the content in the cytosol. The uptake of platinum containing B12 derivatives (1, 2, and 3) is approximately one third compared to the uptake of cisplatin. Similarly it is seen from Fig. 5B that the platinum uptake into cellular nuclei of 1, 2, and 3 was low compared to cisplatin. The low nucleic platinum uptake of 3 was expected as it has a transplatin-based structure. 43, 44 More interestingly, substantial extracellular Pt-release from the B12 structures, which would have resulted in comparative cellular uptake to cisplatin, was not observed. These data indicate that Pt is not released in the extracellular media but taken up together with B12. The complexes are protected when conjugated to the B12 structure. Unexpectedly, the cytosolic uptake of B12 was considerably lower than of [Cbl-OH 2 ] + , 1, 2, and 3 ( Fig. 5 ). This indicated that the observed uptake was not mediated by TC as this protein has similar affinities to B12, 2 (Fig. 4) , and 3.
42 Therefore TC would have allowed similar accumulation of these compounds in cellular components. It was previously reported that B12 derivatives are able to enter cells without the support of TC. This uptake was, nevertheless, less efficient. [45] [46] [47] [48] HeLa cells internalized only 1-2% of free B12
with respect to holo-TC. 45 It was later concluded that free B12 supported cell growth ca. 100 to 1000-fold less efficiently than holo-TC. 49 However, human skin fibroblasts could internalize free B12 better than holo-TC, up to more than 20% were reported. 46 + was internalized and retained better than B12 in human skin , we conclude that the positive charge carried by these compounds allows cells to internalize them better than the neutral B12 derivatives (Fig. 5 ). Behavioral differences between charged and neutral B12 derivatives were also previously observed. 52 It is possible that charged B12
compounds were either distinctly recognized by a B12-specific receptor or they simply passed through the cationic channels on cell membranes. This, however, requires further clarification. In any case, the experimental results highlighted once more the complex multichannel uptake pathways of B12 vitamin analogues including internalization of holo-TC, free B12 derivatives, and charged B12 derivatives. The preferable cellular import of charged B12 compounds should be kept in perspective for future design of pharmaceutical B12 derivatives. Drugs like cisplatin and cytarabine attached to the b-CN À of B12 are released by reducing enzymes in the cytosol. The uptake of Pt into cellular components was always higher than Co (Fig. 5 and 6) . A correlation between cobalt and platinum uptake for the three compounds 1, 2 and 3 is shown in Fig. 7 . The equation for the trend line is y = 1.60X + 4.9. The one outlier point for EATC, cytosol was omitted. The correlation shows that platinum is taken up by a factor of 1.6 higher than cobalt as estimated from the cytosolic and nucleic content.
This observation could reflect a more efficient efflux of Co as compared to platinum.
Conclusions
We reported here comparable uptake in cellular nuclei and cytosol of different B12-drug conjugates, including [{Co}-CN-{cis-PtCl(NH 3 ) 2 . The results underline that these B12 derivatives deliver cispaltin and cisplatin-related drugs to both, cytosol and nuclei, in two different cancer cell lines. It was found that charged B12 derivatives were preferentially taken up into cellular compartments as compared to neutral and native B12. We therefore propose the existence of an additional uptake pathway for charged B12 derivatives in addition to the previously known TC-mediated B12 uptake pathway. Accumulation of released platinum in the nucleus was clearly observed and explains the cytotoxic action of these compounds as previously described. 50 
Experimental

Materials and methods
Analytical high performance liquid chromatography (HPLC) analyses were performed using a Merck-Hitachi L-7000 system equipped with a diode-array UV/Vis spectrometer. Reaction progresses to 2, 3, 7 and 8 were monitored by HPLC. Preparative HPLC purification was performed on Varian Prostar system with two Prostar 215 pumps and a Prostar 320 UV/Vis detector. Reaction progresses to 4, 5, and 6 were assessed by TLC. After purification the B12 derivatives were liophilized. Purity was assessed by analytical HPLC, IR, ESI-MS (Bruker Daltonic) and NMR. NMR spectra were recorded by Bruker DRX 500 MHz spectrometer. Chemical shifts are reported relative to residual solvent protons and carbons. The chemical shifts of 195 Pt NMR spectra were relative to Na 2 PtCl 6 in D 2 O. Phosphate-buffered saline (PBS) contained 137 mM NaCl, 2.6 mM KCl, 6.5 mM Na 2 HPO 4 , and 1.5 mM KH 2 PO 4 . Lysis buffer was prepared from150 mM NaCl, 20 mM HEPES buffer, 1 mM EDTA, 0.5% Triton X-100 (Pharmacia Biotech AB), 1% protease inhibitor cocktail (freshly added), 1 mM NaVO 3 (freshly added). All aqueous solutions for ICPMS measurement were prepared in purified water (418.2 MO) from Milli-Q deionization unit. Standards and samples were prepared in a mixture of HNO 3 0.65% : HCl 0.1%.
HPLC conditions. The analytical HPLC column was Macherey Nagel Nucleosil C18 (5 mm, 100 Å, 250 mm Â 3 mm). The preparative HPLC column was Macherey Nagel Nucleosil C18 (7 mm, 100 Å, 250 mm Â 40 mm) with a flow rate of 35 ml per minute. The following solvent system was used: 0.1% trifluoroacetic acid (TFA) (solvent A), methanol (MeOH) (solvent B). The following solvent gradient was used: gradient 1, 0-5 minutes: 75% A, 5-30 minutes: 0% A.
Syntheses N-tert-Butyloxycarbonyldiamines (4), 54 42 were prepared according to literature procedures. Compounds (5) and (6) were prepared as described in literature 56 but with the following modifications: 2 g (4) (11 mmol) was dissolved in 100 ml MeOH. 1.3 g pyridine-2-carbaldehyde (12 mmol) was added dropwise. After stirring for 3 hours at room temperature, the solvent was removed and the imine dissolved in 50 ml ethanol (EtOH). Reduction with 1.5 g NaBH 4 in 2 h, removal of solvent, re-dissolution in diluted NaHCO 3 and extraction into CH 2 Cl 2 gave the raw product. The purification of 5 was performed with silicagel column (ethylacetate, methanol 1 : 3) (2.8 g, 91%). . 1.5 g (5) was mixed with 1 ml triethylamine in 50 ml EtOH. The mixture was cooled to 0 1C. 600 ml bromo-acetic acid ethylester was added dropwise within 5 min. After stirring for 30 minutes at 0 1C and 16 hours at room temperature, the solvent was removed in vacuo. The residue was dissolved in CH 2 Cl 2 . Extraction was performed with H 2 O. The organic phase was dried over MgSO 4 , filtered and the solvent was removed. The product (6) (1.2 g, 60%) was collected as oil. Synthesis of (8) . 50 mg (82.5 mmol) of (7) was Boc deprotected with 1 ml TFA in 3 ml CH 2 Cl 2 . To a solution of 150 mg (0.11 mmol) B12 in 3.5 ml dry DMSO was added 24 mg (0.15 mmol) CDT. The mixture was stirred for 1 h at 60 1C. Then the Boc-deprotected product was added together with 4 ml dry DMSO and 0.8 ml triethylamine. The reaction was stirred overnight. Diethyl ether was added to precipitate the product. Separation of (8) was performed on preparative HPLC, solvent system 1, gradient 1 (31 mg, 14.5%). . Synthesis of (2). 12 mg (40 mmol) of cisplatin and 6.7 mg (39 mmol) of AgNO 3 were mixed in 1 ml H 2 O. The reaction was stirred in the absence of light at 40 1C for 4 h. AgCl was filtered and the filtrate was added to 22 mg (11.6 mmol) of (8). The reaction was stirred at 45 1C for one day in the absence of light. The product was purified by preparative HPLC, solvent system 1, gradient 1 (20 mg, 80% 
Affinity to transport proteins
Binding to HC/IF and TC was measured by differential scanning fluorimetry (DSF). Details of the method, protein expression and purification was previously described. 42 Uptake measurement with ICPMS. Cells were seeded in T-75 flasks with a seeding density of 3 Â 10 6 cells per flask. The culture medium was 12 ml Roswell Park Memorial Institute (RPMI)-1640 with 10% fetal bovine serum (FCS) and penicillinstreptomycin (100 U ml
À1
). After 1 day of incubation, each flask was treated with 10 mM of a compound. These included cisplatin, B 12 , [Cbl-OH 2 ] + , (1), (2) , and (3). Cells were further maintained in culture for two days. Nucleic and cytosolic fractions were separated according to a previously published procedure with certain modifications. 53 In details, cells were centrifuged for 1 minute at 700 g and room temperature (adherent ELA cells were trypsinized with 0.25% trypsine/EDTA in PBS before this step). The supernatant was discarded. Pellets were washed (3Â) with 5 ml PBS before chemical lysis. 57 Lysis buffer was added.
20 ml of the lysate was spared for protein determination (DC Protein Assay, Bio-Rad). Remaining lysate was centrifuged at 600 g, 4 1C for 5 minutes. The pellet was washed (3Â) with 1 ml NaCl/KCl (30 mM/120 mM) solution to isolate nuclei fraction. The supernatant was centrifuged at 5500 g, 4 1C for 15 minutes. Cytosolic fraction was the supernatant part. The nuclei fractions were digested with 100 ml concentrated HNO 3 . DNA was isolated according to the following procedure. Cells were centrifuged two times for 5 s at 13 000-16 000 g. The precipitate was subsequently lysed with 300 ml lysis solution. 100 ml of Protein Precipitation Solution was added and mixed well. After the proteins were precipitated, the supernatant was transferred into isopropanol (300 ml). This mix is centrifuged for 1 minute at 13 000-16 000 g to collect DNA as precipitate. The DNA fractions were washed with 70% ethanol. DNA hydration solution (50 ml) was then added to the dry DNA. The mixture was then incubated in a water bath at 65 1C for 1 hour to dissolve DNA, followed by incubating at room temperature overnight. Both subcellular fractions were diluted with 0.65% HNO 3 /0.1% HCl for ICPMS measurement.
